ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 34551969

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.

Meric-Bernstam F and 12 others. Cancer Discov, 2022. Cited by 230 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. Papers, record 34551969. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34551969

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
PubMed
Journal
Cancer Discov
PubMed
Year
2022
PubMed
Publication types
Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
230
iCite
Relative citation ratio, by iCite
15.8
iCite
Revised in PubMed
2024-09-12
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Meric-Bernstam FFunda
2Bahleda RRastislav
3Hierro CCinta
4Sanson MMarc
5Bridgewater JJohnhttps://orcid.org/0000-0001-9186-1604
6Arkenau HTHendrik-Tobias
7Tran BBen
8Kelley RKRobin Katehttps://orcid.org/0000-0002-1984-2430
9Park JOJoon Ohhttps://orcid.org/0000-0001-6502-2612
10Javle MMilind

1 to 10 of 13Source PubMed

See all 13 authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Bile Duct NeoplasmsMajor topic
CholangiocarcinomaMajor topic
PyrazolesMajor topic
PyrimidinesMajor topic
PyrrolesMajor topic
Receptor, Fibroblast Growth Factor, Type 1Major topic
Disease-Free Survival
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA016672NCI NIH HHSUnited StatesP30CA016672PubMed and NIH

Source NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127,870,574
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
J Clin Oncol2017https://conductscience.org/library/papers/27870574PubMed
232,932,925Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma.Cancers (Basel)2020https://conductscience.org/library/papers/32932925PubMed
328,615,371A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.Clin Cancer Res2017https://conductscience.org/library/papers/28615371PubMed
431,340,094Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.N Engl J Med2019https://conductscience.org/library/papers/31340094PubMed
523,744,832Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.Cancer Discov2013https://conductscience.org/library/papers/23744832PubMed
629,320,312Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.J Clin Oncol2018https://conductscience.org/library/papers/29320312PubMed
79,136,983Activation of FGF receptors by mutations in the transmembrane domain.Oncogene1997https://conductscience.org/library/papers/9136983PubMed
820,094,046Fibroblast growth factor signalling: from development to cancer.Nat Rev Cancer2010https://conductscience.org/library/papers/20094046PubMed
923,786,770Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.Cancer Res2013https://conductscience.org/library/papers/23786770PubMed
1021,812,026FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone.J Bone Miner Res2011https://conductscience.org/library/papers/21812026PubMed

1 to 10 of 46

See all 46 references

Cited by154

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 230 citations.

PMIDTitleJournalYearIn PapersSource
42,918,853Intrahepatic cholangiocarcinoma: contemporary classification, molecular pathology, and emerging concepts.Virchows Arch2026https://conductscience.org/library/papers/42918853PubMed
42,686,986NatD promotes glioblastoma progression through epigenetic activation of FGFR4 signalling.Exp Mol Med2026https://conductscience.org/library/papers/42686986PubMed
42,679,332Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published Cases.JCO Precis Oncol2026https://conductscience.org/library/papers/42679332PubMed
42,675,086Discovery of a covalent FGFR2-selective inhibitor overcoming clinically-acquired resistance mutations.Nat Commun2026https://conductscience.org/library/papers/42675086PubMed
42,633,326Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.MedComm (2020)2026https://conductscience.org/library/papers/42633326PubMed
42,542,997FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials.Target Oncol2026https://conductscience.org/library/papers/42542997PubMed
42,405,118Advances in the design and discovery of small-molecule tyrosine kinase inhibitors for breast cancer.RSC Adv2026https://conductscience.org/library/papers/42405118PubMed
42,221,979The molecular profile of gliomas in adolescents and young adults.Neurooncol Adv2026https://conductscience.org/library/papers/42221979PubMed
42,190,666An appendiceal cancer organoid biobank identifies phenotypic evolution and druggable dependencies of peritoneal carcinomatosis.Dev Cell2026https://conductscience.org/library/papers/42190666PubMed
42,149,426Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer.Invest New Drugs2026https://conductscience.org/library/papers/42149426PubMed

1 to 10 of 154

See all 154 cited by

Genes15

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
FGF12,246PubTator's text mininghttps://conductscience.org/library/genes/2246NCBI Gene
FGF199,965PubTator's text mininghttps://conductscience.org/library/genes/9965NCBI Gene
FGF32,248PubTator's text mininghttps://conductscience.org/library/genes/2248NCBI Gene
FGF42,249PubTator's text mininghttps://conductscience.org/library/genes/2249NCBI Gene
FGFR12,260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene
FGFR22,263PubTator's text mininghttps://conductscience.org/library/genes/2263NCBI Gene
FGFR32,261PubTator's text mininghttps://conductscience.org/library/genes/2261NCBI Gene
FGFR42,264PubTator's text mininghttps://conductscience.org/library/genes/2264NCBI Gene
GGT12,678PubTator's text mininghttps://conductscience.org/library/genes/2678NCBI Gene

1 to 10 of 15

See all 15 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34551969

GET https://conductscience.org/api/papers/v1/34551969/references?page=2

API referenceFor AI assistants